Northeastern University
College of Professional Studies

QMS Excellence: MDSAP Certification for nuBeam TDS

neutron therapeutics

Final Reflection Paper

By: Divya Vijayan

NUID: 002669034

Professor: Angel Estrada

RGA6300 Practical Applications in Global Regulatory Affairs

Fall 2024

Table of Contents

Executive Summary

1. Organization Overview

For my project, I worked with Neutron Therapeutics, a pioneering company in the field of Boron Neutron Capture Therapy (BNCT). This company is focused on developing the nuBeam platform, the world's only neutron beam system designed specifically for BNCT that meets International Atomic Energy Agency (IAEA) standards for clinical use. The nuBeam platform is at the forefront of medical innovation, offering a unique approach to cancer treatment by using neutron beams to precisely target and destroy cancer cells while minimizing damage to healthy tissue. Neutron Therapeutics is committed to advancing the treatment of cancer through cutting-edge technology and safe, effective treatment options.

As part of the company's global expansion efforts, I was tasked with helping Neutron Therapeutics achieve MDSAP (Medical Device Single Audit Program) certification for the nuBeam Treatment Delivery System (TDS). This certification is crucial for streamlining the regulatory processes in multiple global markets, including the United States (U.S. FDA), Canada (Health Canada), Japan (MHLW/PMDA), and Australia (TGA). My role in the project involved updating the company's Quality Management System (QMS), remediating existing gaps, and preparing for the Stage 2 certification audit to meet international standards and ensure compliance.

2. Regulatory Issue Addressed

The core regulatory challenge I addressed during this project was ensuring Neutron Therapeutics' compliance with global regulatory standards, particularly MDSAP, ISO 9001, and ISO 13485. Achieving MDSAP certification would allow the company to undergo a single, comprehensive audit that would satisfy regulatory requirements in the four major markets. MDSAP is essential for reducing the burden of multiple regulatory audits, making it easier for medical device manufacturers like Neutron Therapeutics to enter and sustain their products in international markets.

The primary task was to ensure that the nuBeam TDS met the stringent requirements set forth by regulatory bodies in each jurisdiction, particularly with respect to QMS processes, SOP updates, internal audits, and corrective actions. This was a complex and multi-faceted challenge that required a deep understanding of regulatory requirements and the ability to translate them into practical, actionable strategies within the company's operational framework.

3. Geographic Areas Addressed

The project focused on achieving certification that would allow Neutron Therapeutics to meet the regulatory requirements in the United States (FDA), Canada (Health Canada), Japan (MHLW/PMDA), and Australia (TGA). MDSAP simplifies the certification process by conducting a single audit that is accepted by all participating regulatory bodies. This geographical approach was particularly significant for Neutron Therapeutics as it sought to expand its presence in international markets.

As each regulatory body has its own unique set of standards, the project required careful consideration of the differences between these regulations and how they are addressed under MDSAP. My role involved aligning Neutron Therapeutics' QMS with these global requirements to ensure compliance and reduce the risk of non-conformities during the audit process.

4. Key Milestones

The project included several key milestones, each of which represented a significant step towards achieving MDSAP certification and aligning the company's QMS with international standards:

- **Milestone 1 (Week 2):** Completion of the initial updates to Standard Operating Procedures (SOPs) to align them with ISO 9001, ISO 13485, and MDSAP standards. These updates were necessary to ensure that all procedures were consistent with the best practices in the medical device industry.
- **Milestone 2 (Week 4):** Finalization of the Quality Management System (QMS) remediation actions based on a thorough gap analysis. This step was essential for identifying deficiencies and implementing corrective actions.
- **Milestone 3 (Week 6):** Conducting a readiness assessment for the Stage 2 certification audit. This assessment was a critical step in identifying any remaining gaps and ensuring that the company was fully prepared for the official audit.
- **Milestone 4 (Week 8):** Performance of a mock audit to test the company's readiness and address any lingering compliance gaps. Mock audits serve as a valuable tool for identifying potential issues before the official audit.
- **Milestone 5 (Week 10):** Implementation of corrective actions from the mock audit, finalizing all audit preparations to ensure a smooth and successful Stage 2 certification audit.
- **Milestone 6 (Week 12):** Undergoing the official Stage 2 certification audit and addressing any final findings. This step was the culmination of all previous efforts and marked the final phase of the project.

5. Key Deliverables

The key deliverables for the project included several critical documents and actions that were necessary for compliance:

- Updated SOPs that were aligned with ISO 9001, ISO 13485, and MDSAP standards.
- A comprehensive QMS remediation plan based on the findings from the gap analysis.
- Internal audit reports and corrective action plans to address compliance issues.
- Progress tracking and readiness documents to ensure that the company was prepared for the Stage 2 certification audit.

Challenges and Solutions

1. Challenges Faced

- **Complexity of Multi-Standard Compliance:** One of the most significant challenges I encountered was the complexity of aligning Neutron Therapeutics' QMS with multiple international standards. While ISO 9001, ISO 13485, and MDSAP have overlapping requirements, they also have distinct differences that needed to be addressed. Balancing the requirements of these standards while ensuring that they were all adequately met was a complex task that required attention to detail and a strategic approach.
- **Continuous Monitoring for Compliance:** Maintaining ongoing compliance and audit readiness throughout the process was another challenge. As the company worked to implement corrective actions and updates, it was crucial to establish systems for continuous monitoring and assessment to ensure that any new compliance gaps were identified and addressed promptly.
- **Alignment Across Departments:** Coordinating with various departments to implement SOP updates and ensure alignment with the overall compliance objectives was a significant challenge. The process required effective communication and collaboration between Quality Assurance, Regulatory Affairs, and other teams to ensure consistency and alignment with regulatory requirements.

2. Approach to Challenges

To address these challenges, I took a methodical approach to ensure that all areas of the project were covered comprehensively. This included:

- **Structured Gap Analysis:** I conducted a detailed gap analysis to identify compliance deficiencies and provided actionable recommendations to address them. This gap analysis was instrumental in ensuring that all critical areas were reviewed and that corrective actions were implemented effectively.
- **Continuous Improvement Process:** I established a continuous monitoring system to maintain readiness for audits and ensure that any compliance gaps were addressed promptly. Regular audits and assessments allowed for proactive identification of issues and timely corrective actions.
- **Clear Communication and Coordination:** I worked closely with different departments to ensure that updates to SOPs and QMS processes were implemented consistently across the organization. Regular meetings and updates helped ensure alignment and facilitated effective collaboration.

3. Success of Approach

The approach I implemented proved to be effective. By addressing the challenges proactively, I was able to help Neutron Therapeutics complete the necessary updates to its SOPs and QMS, conduct successful mock audits, and achieve readiness for the Stage 2 certification audit. The corrective actions and improvements were successful in meeting MDSAP and ISO standards, and the company was well-prepared for the final audit.

Reflection on Revisions

If given the opportunity to start the project again, there are a few things I would approach differently:

- **Enhanced Communication with the Sponsor:** While I maintained regular communication, I would aim to increase the frequency of discussions to ensure that all updates and revisions to SOPs were clearly understood by the sponsor in real-time. This would help in avoiding potential delays in the approval process.
- **More Focused Gap Analysis:** Although the gap analysis was thorough, I would place more emphasis on identifying potential issues that could arise during the Stage 2 audit. This would allow for quicker resolution and a smoother transition to the final audit.
- **Better Time Management:** I would also adjust the timelines for internal reviews and mock audits to ensure that all corrective actions were fully tested before the official audit. This would reduce the risk of overlooking any last-minute issues that might arise.

Conclusion

This project has been an invaluable learning experience and has deepened my understanding of the complexities involved in regulatory compliance in the medical device industry. The challenges I faced have helped me develop problem-solving skills, enhanced my understanding of regulatory frameworks, and improved my ability to communicate technical information effectively. The experience has reinforced the importance of thorough documentation, clear communication, and continuous improvement in ensuring successful regulatory outcomes.

Ultimately, the skills I gained from this project will significantly contribute to my professional growth in regulatory affairs. This experience has provided me with practical, real-world insights into the regulatory certification process and has better prepared me for future challenges in the field.

References

1. U.S. Food and Drug Administration. (2024). *MDSAP Assessment Procedures and Forms* retrieved from https://www.fda.gov/media/87399/download
2. U.S. Food and Drug Administration. (2019). *Medical Device Reporting* (21 CFR Part 803). Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803
3. International Organization for Standardization. (2016). *ISO 13485:2016 - Medical devices - Quality management systems - Requirements for regulatory purposes.* Geneva, Switzerland: ISO. Available for purchase at https://www.iso.org/standard/59752.html
4. International Organization for Standardization. (2016). *ISO 13485:2016 - Medical devices - Quality management systems - Requirements for regulatory purposes, Section 7.3 - Design and Development.* Geneva, Switzerland: ISO. Available for purchase at https://www.iso.org/standard/59752.html

5. International Organization for Standardization. (2019). *ISO 14971:2019 - Medical devices - Application of risk management to medical devices.* Geneva, Switzerland: ISO. Available for purchase at https://www.iso.org/standard/72704.html
6. International Organization for Standardization. (2016). *ISO 13485:2016 - Medical devices - Quality management systems - Requirements for regulatory purposes.* Geneva, Switzerland: ISO. Available for purchase at https://www.iso.org/standard/59752.html
7. International Electrotechnical Commission. (2015). *IEC 62366-1:2015 - Medical devices - Part 1: Application of usability engineering to medical devices.* Geneva, Switzerland: IEC. Available for purchase at https://webstore.iec.ch/publication/22798
8. International Organization for Standardization. (2016). *ISO 13485:2016 - Medical devices - Quality management systems - Requirements for regulatory purposes.* Geneva, Switzerland: ISO. Available for purchase at https://www.iso.org/standard/59752.html
9. U.S. Food and Drug Administration. (2019). *Quality System Regulation* (21 CFR Part 820, Section 820.30). Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820
10. European Parliament and Council. (2017). *Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices.* Official Journal of the European Union, L 117, 1–175. Available at https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745
11. *SOP Guidance documents and files, Neutron therapeutics* (n.d.) Confidential.
12. *How the MDSAP Grading System Works [Quick Guide]*. (n.d.). https://www.greenlight.guru/blog/mdsap-grading-system